Cancer and Metastasis Reviews

Papers
(The H4-Index of Cancer and Metastasis Reviews is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities358
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer226
Obesity and cancer221
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms142
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions140
The functions and modifications of tRNA-derived small RNAs in cancer biology118
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression107
Clonal tracking in cancer and metastasis91
Regulation of dormancy during tumor dissemination: the role of the ECM84
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?71
Targeting lipid metabolism in cancer: neuroblastoma69
CAR T-cell therapy to treat multiple myeloma: current state and future directions68
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer61
p73 isoforms meet evolution of metastasis60
Cell-cell interactions mediating primary and metastatic breast cancer dormancy59
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review56
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives47
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?47
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond46
Biography—Mathieu Boissan, Pharm.D., Ph.D45
Preface42
Neuropeptide Y in cancer—biological functions and potential clinical implications40
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer40
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance39
Biographies39
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance37
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications36
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy36
The role of cancer cell bioenergetics in dormancy and drug resistance36
Short-chain fatty acids in cancer pathogenesis36
Clusterin: a marker and mediator of chemoresistance in colorectal cancer35
Tumor necrosis factor superfamily signaling: life and death in cancer35
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy35
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development35
Clinical interventions to break the obesity and cancer link: a narrative review34
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions34
0.17640614509583